Eptinezumab for migraine prevention in patients 50 years or older

OBJECTIVE: To evaluate the efficacy and safety of eptinezumab versus placebo in patients ≥50 years old with episodic (EM) or chronic migraine (CM). MATERIALS AND METHODS: This post hoc analysis included data from two phase 3, parallel‐group, randomized, double‐blind, placebo‐controlled studies in ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Vincent, Tassorelli, Cristina, Ettrup, Anders, Hirman, Joe, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305510/
https://www.ncbi.nlm.nih.gov/pubmed/35218203
http://dx.doi.org/10.1111/ane.13603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305510/
https://www.ncbi.nlm.nih.gov/pubmed/35218203
http://dx.doi.org/10.1111/ane.13603

Ejemplares similares